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Non-linear model to estimate gametocyte clearance time 
A non-linear model was fit in SAS 9.3 (SAS Institute, North Carolina, United States) to estimate the 
rate of gametocyte clearance in study participants allocated to different treatment regimens:  
 =	
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where Gt represents the proportion of individuals with gametocytes at time t. r is the rate with which 
gametocytes are cleared and depends on the treatment received: 
 = 	 (
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where r0 corresponds to the clearance rate in the artemether-lumefantrine only group; and I1 and I2 are 
indicator variables representing the 0.25 mg/kg and the 0.40 mg/kg primaquine dose arms, 
respectively. a and b represent the effects of the different primaquine doses on the rate of gametocyte 
clearance and are estimated from the data.   
 
Haematological changes after treatment 
Finger-prick measurements 
219 children had haemoglobin levels quantified by Hemocue photometer on day 0. For those study 
subjects without Hemocue-derived haemoglobin levels in the beginning of the follow-up, 
measurements done at screening were used as baseline: the median (interquartile range) interval 
between screening and the day 0 of follow-up was 2 (1 – 2) days. The majority (227/360) of study 
participants had haemoglobin levels measured on five follow-up visits after day 0; 9 children had 2 or 
less measurements. When all enrolled individuals are considered, regardless of the number of 
Hemocue measurements during follow-up, the average (95% CI) maximal fall in haemoglobin 
concentrations after treatment initiation was -0.60 (-0.81 - -0.39), -0.75 (-0.95 - -0.56) and -0.84 (-
1.08 - -0.61) g/dL in the AL-placebo arm, the 0.25 mg/kg primaquine dose arm and the 0.40 
primaquine dose arm, respectively (N=355, P=0.12). 
 Venous blood measurements 
During follow-up, haematological parameters were also measured on venous blood samples collected 
on days 0, 3 and 7. When using haemoglobin levels measured on these venous samples to assess 
haemolysis, the average (95% CI) maximal fall in haemoglobin concentrations after treatment 
initiation was -0.19 (-0.30 - -0.07), -0.30 (-0.45 - -0.14) and -0.33 (-0.45 - -0.20) g/dL in the AL-
placebo arm (N=110), the 0.25 mg/kg primaquine dose arm (N=122) and the 0.40 primaquine dose 
arm (N=119), respectively (P=0.32).  
 
Reticulocytes 
16 children had reticulocyte levels higher than 5% at enrolment. During follow-up, in 47 scheduled 
visits (17 on day 3 and 30 on day 7), reticulocyte levels were above 5%: 14, 18 and 15 in the AL-
placebo, 0.25 mg/kg primaquine and 0.40 mg/kg primaquine arms, respectively. Median absolute 
reticulocyte count at enrolment was 88 (range 66 – 113) x103 reticulocytes per µL; absolute levels 
increased on day 7 versus day 0 in 78/101, 93/116 and 89/110 children in the AL-placebo, 0.25 mg/kg 
primaquine and 0.40 mg/kg primaquine arms, respectively. There was a positive correlation between 
increase in reticulocyte levels during the first week of follow-up and haemoglobin drop by day 7 in 
the primaquine arms (Spearman's rank correlation coefficient 0.18 [P=0.03], N=141). 
 
Parasitological criterion 
20 children with less than 1,000 asexual falciparum parasites per µL and no gametocytes at screening 
were mistakenly enrolled. They were equally distributed in the different study arms: 6, 7 and 7 were 
enrolled in the AL-placebo, the 0.25 mg/kg primaquine and the 0.40 mg/kg primaquine arms, 
respectively. 3, one from each study arm, of these 20 children had gametocytes on day 0 and were 
included in the gametocyte clearance analysis. Additionally, one child, from the AL-placebo group, 
had P. malariae infection detected by microscopy at enrolment, but not during follow-up visits. Data 
from these children were included in analyses presented in this manuscript. 
 
 
 
 
 
 
Tables 
Table S1. Prevalence of microscopically-detectable gametocytes during follow-up in children with patent gametocytes on day 0. AL = artemether-
lumefantrine; PQ = primaquine 
 
      
 
AL AL + 0.25 mg/kg PQ AL + 0.40 mg/kg PQ 
 
% (n/N) % (n/N) % (n/N) 
    
Day 2 38.6 (17/44) 35.4 (17/48) 36.5 (19/52) 
Day 3 34.1 (15/44) 35.4 (17/48) 23.5 (12/51) 
Day 7 20.9 (9/43) 10.4 (5/48) 5.8 (3/52) 
Day 10 19.5 (8/41) 4.1 (2/49) 0.0 (0/51) 
Day 14 15.4 (6/39) 0.0 (0/44) 0.0 (0/45) 
 
      
 
Table S2. Gametocyte levels (per µL) measured by qRT-PCR during gametocyte-positive visits in children with patent gametocytes on day 0. AL = 
artemether-lumefantrine; PQ = primaquine 
 
        
 
AL AL + 0.25 mg/kg PQ AL + 0.40 mg/kg PQ AL vs. AL + 0.25mg/kg PQ AL vs. AL + 0.40 mg/kg PQ 
 
Median (IQR, N) Median (IQR, N) Median (IQR, N) P-value P-value 
   
  
 
Day 0 17.26 (7.21 – 45.08, 43) 18.62 (7.76 – 75.27, 48) 16.63 (7.18 – 39.99, 49) 0.58 0.83 
Day 2 2.33 (0.81 – 10.21, 41) 2.25 (0.75 – 5.83, 42) 2.52 (0.85 – 9.70, 47) 0.57 0.97 
Day 3 0.64 (0.08 – 2.64, 38)  0.87 (0.30 – 2.28, 37) 0.70 (0.17 – 2.49, 48) 0.35 0.67 
Day 7 0.48 (0.12 – 1.28, 28) 0.14 (0.08 – 0.45, 17) 0.15 (0.05 – 0.24, 15) 0.12 0.02 
Day 10 0.49 (0.17 – 1.40, 27) 0.12 (0.08 – 0.54, 14) 0.13 (0.05 – 0.31, 11) 0.07 0.008 
Day 14 0.30 (0.18 – 0.50, 17) 0.10 (0.10 – 0.66, 5) 0.15 (0.12 – 0.53, 9) 0.56 0.77 
 
        
 
 
 
Table S3. Adverse Events by treatment arm. In (A), adverse events (AEs) are presented by severity 
and causality; in (B), by clinical condition. AL = artemether-lumefantrine; PQ = primaquine 
(A)  
Adverse Events   
by Severity and causality* 
AL 
only 
AL + 
 0.25 mg/kg PQ 
AL + 
 0.40 mg/kg PQ 
Any AE 15 18 24 
Mild AEs 7 7 9 
Mild AEs possibly related to study 2 1 4 
Moderate AES 8 11 15 
Moderate AEs possibly related to study 1 0 0 
Severe AEs 0 0 0 
*In total 48 children developed AEs during follow-up; 8 had 2 or more AEs.
 
 
(B) 
Adverse Event AL only 
AL +  
0.25 mg/kg PQ 
AL +  
0.40 mg/kg PQ 
Bronchitis 2 4 6 
Fever 2 4 5 
Abdominal Pain 1 1 0 
Vomitingα 2 2 2 
Uncomplicated Malaria 2 1 2 
Rhinitis/ Rhino-Bronchitis 1 1 1 
Otitis 0 0 2 
Dysentery 1 2 3 
Epistaxis 0 0 1 
Dental Pain 1 0 0 
High transaminase levels 1 0 0 
Palpebral inflammation 1 0 0 
Muscle pain (Neck) 0 1 0 
Wound 1 1 1 
Trauma on left foot 0 1 0 
Inflammation (left foot) 0 0 1 
α
 5/6 vomiting episodes occurred on days 0 or 1; for all these 5 visits, study drug was re-administered. 1 
child vomited on day 3 after treatment initiation  
 
 
 
Table S4. Maximal percentage drop in haemoglobin levels, relative to baseline (enrolment or 
screening), by treatment arm. AL = artemether-lumefantrine; PQ = primaquine. 
Maximal % drop in haemoglobin 
Mean % (95% Confidence Interval)   
AL only 5.7 (3.3 - 8.1) 
AL + 0.25 mg/kg PQ 7.8 (5.8 - 9.8) 
AL + 0.40 mg/kg PQ    9.9 (7.9 - 11.9) 
 
 
Table S5. Number of participants with substantial haemoglobin drops (2 or more g/dL) during follow-
up (N=35). AL = artemether-lumefantrine; PQ = primaquine. 
Haemoglobin drop (in g/dL) 
 2 - 3 3 – 4 > 4 
AL only 6 3 0 
AL + 0.25 mg/kg PQ 11 0 1 
AL + 0.40 mg/kg PQ 9 4 1 
 
 
 
 
 
 
 
 
 
Table S6. Laboratory abnormalities during follow-up (days 3 and 7). In addition to the findings 
presented in this table, 7 children presented white blood cell counts below 4,000 cells per µL during 
follow-up: 2, 3 and 2 in the AL-placebo arm, the 0.25 mg/kg primaquine dose arm and the 0.40 mg/kg 
primaquine dose arm, respectively. AL = artemether-lumefantrine; PQ = primaquine. 
White blood cell counts > 15,000 / μL 
Treatment arm Number of children 
AL only 3 
AL + 0.25 mg/kg PQ 2 
AL + 0.40 mg/Kg PQ 1 
Platelet  count  < 150,000 / μL 
Treatment arm Number of children 
AL only 4 
AL + 0.25 mg/kg PQ 5 
AL + 0.40 mg/Kg PQ 4 
Creatinine levels above upper limit of normal range*
,φ
 
Treatment arm Number of children 
AL only 2 
AL + 0.25 mg/kg PQ 1 
AL + 0.40 mg/Kg PQ 1 
Liver transaminases levels above upper limit of normal range
¥,¤
 
Treatment arm Number of children 
AL only 4 
AL + 0.25 mg/kg PQ 2 
AL + 0.40 mg/Kg PQ 1 
Total bilirubin levels above 20 μmol/L 
Treatment arm Number of children
α
 
AL only 2 
AL + 0.25 mg/kg PQ 5 
AL + 0.40 mg/Kg PQ 7 
* < 6 years: 44.2 μmol/L; 6 - 10 years: 53.0 μmol/L; 10-15 years: 61.9 μmol/L 
φ 
2/4 had normal creatinine levels by the end of the follow-up 
¥
AST: < 6 years: 79 U/L; 6 - 10 years: 74 U/L; 10-15 years: 69 U/L 
ALT: < 6 years: 80 U/L; 6 - 10 years: 78 U/L; 10-15 years: 76 U/L 
¤ 
In 6/7 children with liver transaminases above normal range, levels decreased during the follow-up 
α
3 children, one in each treatment arm, had bilirubin levels above 20 μmol/L at enrolment
 
 
 
 
Table S7. Summary of previous studies assessing post-artemether lumefantrine transmission potential. Mosquito infection rates in the study by Ouédraogo 
and colleagues were based on PCR; the other studies listed in the table used microscopy to assess oocyst positivity. 
 
 
Study 
type 
Setting Inclusion trial 
Gametocyte 
positivity required 
for feeding assay? 
Number 
of 
assays 
Time from 
treatment 
initiation 
(feeding assay) 
Number of 
infected 
mosquitoes in 
feeding assay (AL 
only group) 
Number of 
infectious 
individuals in 
feeding assay (AL 
only group) 
Sutherland et al. 2005 RCT* Gambia 
Children with 
uncomplicated 
malaria 
Yes 10 Day 7 0/196 (0) 0/10 
Bousema et al. 2006 RCT Kenya 
Children with 
uncomplicated 
malaria 
No 25 Day 14 27/750 (3.6%) 15/25 
Sawa et al. 2013 RCT Kenya 
Children with 
uncomplicated 
malaria 
No 77 Day 7 43/2293 (1.9%) 24/77 
Ouédraogo et al. 2015 RCT Burkina Faso 
Asymptomatic 
adults 
No** 68 Days 1 and 7 4/560 (0.7%) - 
* randomised controlled trial  
      
** Although gametocyte positivity was not a criterion for inclusion in feeding assays, only children with positive Pfs25 mRNA NASBA results had mosquito infection status 
assessed 
Sutherland CJ et al. Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med 2005, 2(4):e92 
Bousema JT et al: Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis 2006, 193(8):1151-1159 
Sawa P et al.  Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 2013, 207(11):1637-1645 
Ouédraogo et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clin 
Infect Dis. 2015. 
 
 
